Pancreatic Ductal Adenocarcinoma Clinical Trials

186 recruitingLast updated: June 17, 2026

There are 186 actively recruiting pancreatic ductal adenocarcinoma clinical trials across 45 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Pancreatic Ductal Adenocarcinoma Trials at a Glance

186 actively recruiting trials for pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 2 with 82 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running pancreatic ductal adenocarcinoma studies include Revolution Medicines, Inc., City of Hope Medical Center, and AstraZeneca.

Browse pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for Pancreatic Ductal Adenocarcinoma? There are currently 91 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 186 trials

Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 2Phase 3

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled11 locationsNCT07490301
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
Verastem, Inc.180 enrolled8 locationsNCT07644559
Recruiting
Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled17 locationsNCT07562152
Recruiting
Phase 2

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited39 enrolled2 locationsNCT07450859
Recruiting
Phase 2Phase 3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled188 locationsNCT06989437
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.448 enrolled12 locationsNCT06835569
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 2

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma
University of Pennsylvania100 enrolled1 locationNCT07199764
Recruiting
Phase 2

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT05851924
Recruiting
Phase 2

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (mPDAC)
University of California, San Diego43 enrolled1 locationNCT06790602
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1Phase 2

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute35 enrolled1 locationNCT07214298
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Perspective Therapeutics112 enrolled8 locationsNCT06710756
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled5 locationsNCT07491445
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 2

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Pancreatic Ductal AdenocarcinomaGastric/Gastroesophageal Junction AdenocarcinomaCLDN18.2 Positive
Innovent Biologics (Suzhou) Co. Ltd.389 enrolled1 locationNCT07483554